deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT01486784

A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Acute Myelogenous Leukemia
Interventions Birinapant
Updated 11 times since 2017 Last updated: Jun 23, 2021 Started: Nov 30, 2011 Primary completion: Nov 30, 2014 Completion: Apr 30, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Abramson Cancer Center at Penn Medicine

See all terminations from Abramson Cancer Center at Penn Medicine

Other Acute Myelogenous Leukemia trials with similar outcome

Browse all Acute Myelogenous Leukemia trials

Listed as NCT01486784, this PHASE1/PHASE2 trial focuses on Acute Myelogenous Leukemia and remains terminated or withdrawn. Sponsored by Abramson Cancer Center at Penn Medicine, it has been updated 11 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotActive Not Recruiting~Sep 2018 – ~May 2020 · 20 months · monthly snapshotActive Not Recruiting~May 2020 – ~Jan 2021 · 8 months · monthly snapshotTerminated~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshotTerminated~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshotTerminated~Sep 2021 – ~Apr 2023 · 19 months · monthly snapshotTerminated~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Apr 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Sep 2021 — Apr 2023 [monthly]

    Terminated PHASE1_PHASE2

  5. Jun 2021 — Sep 2021 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Jan 2021 — Jun 2021 [monthly]

    Terminated PHASE1_PHASE2

  2. May 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  3. Sep 2018 — May 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations